From: Identifying gaps in the continuum of care for hypertension and diabetes in two Indian communities
 | Platform type | Public Hospital | CHC | PHC | SHC | Private Hospital | Private Clinic |
---|---|---|---|---|---|---|---|
Shimla | |||||||
 Hypertension | Calcium Channel Blockers | 100 | 100 | 50 | 0 | 100 | 0 |
Beta Blocker | 100 | 100 | 25 | 0 | 75 | 0 | |
ACE Inhibitors | 50 | 100 | 50 | 0 | 75 | 0 | |
 Diabetes | Biguanides | 100 | 100 | 75 | 0 | 75 | 0 |
Sulphonylureas | 0 | 100 | 50 | 0 | 75 | 0 | |
Insulin | 50 | 0 | 0 | 0 | 75 | 0 | |
 High Cholesterol | Statin | 50 | 0 | 0 | 0 | 75 | 0 |
 Other | Salicylate (aspirin) | 50 | 50 | 25 | 0 | 75 | 0 |
Diuretic | 100 | 0 | 0 | 0 | 75 | 0 | |
Udaipur | |||||||
 Hypertension | Beta Blocker | 100 | 100 | 60 | 0 | 60 | 0 |
Calcium Channel Blockers | 100 | 100 | 60 | 0 | 40 | 0 | |
ACE Inhibitors | 100 | 0 | 0 | 0 | 40 | 0 | |
 Diabetes | Biguanides | 100 | 100 | 80 | 0 | 40 | 0 |
Sulphonylureas | 100 | 50 | 60 | 0 | 40 | 0 | |
Insulin | 100 | 0 | 20 | 0 | 40 | 0 | |
 High Cholesterol | Statin | 100 | 0 | 0 | 0 | 40 | 0 |
 Other | Diuretic | 100 | 100 | 80 | 0 | 40 | 0 |
Salicylate (aspirin) | 50 | 50 | 40 | 0 | 40 | 0 |